TBC1D10C and B-cell non-Hodgkin lymphoma: Carabin has also been reported to be a novel negative regulator of B-cell function in systemic lupus erythematosus (SLE) and B-cell lymphoma through inhibiting the crosstalk between BCR and TLR9 pathways (11, 12).